Merck expands its Investment Fund Merck Ventures

Total fund size doubled to up to €300 million.

“Our biopharma venture fund has been very successful to date. Now we are applying this successful approach to all three business sectors of Merck,” said Stefan Oschmann, Chairman of the Executive Board and CEO of Merck. “The new fund now reflects our businesses and, with its fourth arm, is open to investing in new businesses as we scout continuously for innovative ideas, for example in the area of digitalization.”

With its four teams, the new Merck Ventures fund follows the former Merck biopharma ventures blueprint, which has been in place since 2009. The biopharma fund was at the basis of several success stories such as Galecto Biotech (galectin modulators for the treatment of severe diseases), Asceneuron (Merck spin-off developing innovative drugs to help people with Alzheimer’s disease) and Metabomed (novel drugs against targets in the field of cancer cell metabolism), among others.

“The investments of Merck Ventures will be aligned with the strategic interests of Merck, though formally separated by a Chinese wall,” said Roel Bulthuis, Managing Director of Merck Ventures. “With our infrastructure of a leading science and technology company we provide start-ups with the support they need to make their vision a commercial success.”

The investment teams come with significant domain expertise and will provide a tailored investment approach across industries. Each team has the capacity to engage in seed-stage company creation, early-stage syndicated investments and Merck spin-off creation and funding. Like the former biopharma venture fund, the new Merck Venture fund is managed by a global team headed by Roel Bulthuis.